

Jaime Dougherty (MN)  
 Jeffrey Douglass (ME)  
 Christopher Nonnenkamp (MO)  
 Angel Velez-Cruz (NJ)

The drivers were included in docket number FMCSA–2014–0212, FMCSA–2017–0253, FMCSA–2020–0049, or FMCSA–2021–0025. Their exemptions are applicable as of August 13, 2023, and will expire on August 13, 2025.

## V. Conditions and Requirements

The exemptions are extended subject to the following conditions: (1) each driver must remain seizure-free and maintain a stable treatment during the 2-year exemption period; (2) each driver must submit annual reports from their treating physicians attesting to the stability of treatment and that the driver has remained seizure-free; (3) each driver must undergo an annual medical examination by a certified ME, as defined by § 390.5; and (4) each driver must provide a copy of the annual medical certification to the employer for retention in the driver's qualification file, or keep a copy of his/her driver's qualification file if he/she is self-employed. The driver must also have a copy of the exemption when driving, for presentation to a duly authorized Federal, State, or local enforcement official. The exemption will be rescinded if: (1) the person fails to comply with the terms and conditions of the exemption; (2) the exemption has resulted in a lower level of safety than was maintained before it was granted; or (3) continuation of the exemption would not be consistent with the goals and objectives of 49 U.S.C. 31136(e) and 31315(b).

## VI. Preemption

During the period the exemption is in effect, no State shall enforce any law or regulation that conflicts with this exemption with respect to a person operating under the exemption.

## VII. Conclusion

Based on its evaluation of the five exemption applications, FMCSA renews the exemptions of the aforementioned drivers from the epilepsy and seizure disorders prohibition in § 391.41(b)(8). In accordance with 49 U.S.C. 31136(e) and 31315(b), each exemption will be valid for 2 years unless revoked earlier by FMCSA.

**Larry W. Minor,**

*Associate Administrator for Policy.*

[FR Doc. 2023–16596 Filed 8–2–23; 8:45 am]

**BILLING CODE 4910-EX-P**

## DEPARTMENT OF TRANSPORTATION

### Federal Motor Carrier Safety Administration

[Docket No. FMCSA–2023–0035]

### Qualification of Drivers; Exemption Applications; Epilepsy and Seizure Disorders

**AGENCY:** Federal Motor Carrier Safety Administration (FMCSA), Department of Transportation (DOT).

**ACTION:** Notice of applications for exemption; request for comments.

**SUMMARY:** FMCSA announces receipt of applications from 21 individuals for an exemption from the prohibition in the Federal Motor Carrier Safety Regulations (FMCSRs) against persons with a clinical diagnosis of epilepsy or any other condition that is likely to cause a loss of consciousness or any loss of ability to control a commercial motor vehicle (CMV) to drive in interstate commerce. If granted, the exemptions would enable these individuals who have had one or more seizures and are taking anti-seizure medication to operate CMVs in interstate commerce.

**DATES:** Comments must be received on or before September 5, 2023.

**ADDRESSES:** You may submit comments identified by the Federal Docket Management System Docket No. FMCSA–2023–0035 using any of the following methods:

- *Federal eRulemaking Portal:* Go to [www.regulations.gov/](https://www.regulations.gov/), insert the docket number (FMCSA–2023–0035) in the keyword box and click “Search.” Next, click on the “Comment” button. Follow the online instructions for submitting comments.

- *Mail:* Dockets Operations; U.S. Department of Transportation, 1200 New Jersey Avenue SE, West Building Ground Floor, Washington, DC 20590–0001.

- *Hand Delivery:* West Building Ground Floor, 1200 New Jersey Avenue SE, Washington, DC 20590–0001 between 9 a.m. and 5 p.m. ET Monday through Friday, except Federal holidays.

- *Fax:* (202) 493–2251.

To avoid duplication, please use only one of these four methods. See the “Public Participation” portion of the **SUPPLEMENTARY INFORMATION** section for instructions on submitting comments.

**FOR FURTHER INFORMATION CONTACT:** Ms. Christine A. Hydock, Chief, Medical Programs Division, FMCSA, DOT, 1200 New Jersey Avenue SE, Room W64–224, Washington, DC 20590–0001, (202) 366–4001, [fmcsamedical@dot.gov](mailto:fmcsamedical@dot.gov). Office hours are 8:30 a.m. to 5 p.m. ET Monday

through Friday, except Federal holidays. If you have questions regarding viewing or submitting material to the docket, contact Dockets Operations, (202) 366–9826.

### SUPPLEMENTARY INFORMATION:

#### I. Public Participation

##### A. Submitting Comments

If you submit a comment, please include the docket number for this notice (Docket No. FMCSA–2023–0035), indicate the specific section of this document to which each comment applies, and provide a reason for each suggestion or recommendation. You may submit your comments and material online or by fax, mail, or hand delivery, but please use only one of these means. FMCSA recommends that you include your name and a mailing address, an email address, or a phone number in the body of your document so that FMCSA can contact you if there are questions regarding your submission.

To submit your comment online, go to <https://www.regulations.gov/docket/FMCSA-2023-0035/document>. Next, choose the first notice listed, click the “Comment” button, and type your comment into the text box on the following screen. Choose whether you are submitting your comment as an individual or on behalf of a third party and then submit.

If you submit your comments by mail or hand delivery, submit them in an unbound format, no larger than 8½ by 11 inches, suitable for copying and electronic filing. FMCSA will consider all comments and material received during the comment period.

##### B. Viewing Comments

To view comments go to [www.regulations.gov](https://www.regulations.gov/). Insert the docket number (FMCSA–2023–0035) in the keyword box and click “Search.” Next, choose the first notice listed, and click “Browse Comments.” If you do not have access to the internet, you may view the docket online by visiting Dockets Operations on the ground floor of the DOT West Building, 1200 New Jersey Avenue SE, Washington, DC 20590–0001, between 9 a.m. and 5 p.m. ET Monday through Friday, except Federal holidays. To be sure someone is there to help you, please call (202) 366–9317 or (202) 366–9826 before visiting Dockets Operations.

##### C. Privacy Act

In accordance with 49 U.S.C. 31315(b)(6), DOT solicits comments from the public on the exemption request. DOT posts these comments,

without edit, including any personal information the commenter provides, to [www.regulations.gov](http://www.regulations.gov). As described in the system of records notice DOT/ALL 14 (Federal Docket Management System), which can be reviewed at <https://www.transportation.gov/individuals/privacy/privacy-act-system-records-notices>, the comments are searchable by the name of the submitter.

## II. Background

Under 49 U.S.C. 31136(e) and 31315(b), FMCSA may grant an exemption from the FMCSRs for no longer than a 5-year period if it finds such exemption would likely achieve a level of safety that is equivalent to, or greater than, the level that would be achieved absent such exemption. The statutes also allow the Agency to renew exemptions at the end of the 5-year period. FMCSA grants medical exemptions from the FMCSRs for a 2-year period to align with the maximum duration of a driver's medical certification.

The 21 individuals listed in this notice have requested an exemption from the epilepsy and seizure disorders prohibition in 49 CFR 391.41(b)(8). Accordingly, the Agency will evaluate the qualifications of each applicant to determine whether granting the exemption will achieve the required level of safety mandated by statute.

The physical qualification standard for drivers regarding epilepsy found in § 391.41(b)(8) states that a person is physically qualified to drive a CMV if that person has no established medical history or clinical diagnosis of epilepsy or any other condition which is likely to cause the loss of consciousness or any loss of ability to control a CMV.

In addition to the regulations, FMCSA has published advisory criteria<sup>1</sup> to assist medical examiners (MEs) in determining whether drivers with certain medical conditions are qualified to operate a CMV in interstate commerce.

The criteria states that if an individual has had a sudden episode of a non-epileptic seizure or loss of consciousness of unknown cause that did not require anti-seizure medication, the decision whether that person's condition is likely to cause the loss of consciousness or loss of ability to control a CMV should be made on an individual basis by the ME in consultation with the treating physician.

<sup>1</sup> These criteria may be found in APPENDIX A TO PART 391—MEDICAL ADVISORY CRITERIA, section H. *Epilepsy*: § 391.41(b)(8), paragraphs 3, 4, and 5, which is available on the internet at <https://www.gpo.gov/fdsys/pkg/CFR-2015-title49-vol5/pdf/CFR-2015-title49-vol5-part391-appA.pdf>.

Before certification is considered, it is suggested that a 6-month waiting period elapse from the time of the episode. Following the waiting period, it is suggested that the individual have a complete neurological examination. If the results of the examination are negative and anti-seizure medication is not required, then the driver may be qualified.

In those individual cases where a driver has had a seizure or an episode of loss of consciousness that resulted from a known medical condition (e.g., drug reaction, high temperature, acute infectious disease, dehydration, or acute metabolic disturbance), certification should be deferred until the driver has recovered fully from that condition, has no existing residual complications, and is not taking anti-seizure medication.

Drivers who have a history of epilepsy/seizures, off anti-seizure medication, and seizure-free for 10 years, may be qualified to operate a CMV in interstate commerce. Interstate drivers with a history of a single unprovoked seizure may be qualified to drive a CMV in interstate commerce if seizure-free and off anti-seizure medication for a 5-year period or more.

As a result of MEs misinterpreting advisory criteria as regulation, numerous drivers have been prohibited from operating a CMV in interstate commerce based on the fact that they have had one or more seizures and are taking anti-seizure medication, rather than an individual analysis of their circumstances by a qualified ME based on the physical qualification standards and medical best practices.

On January 15, 2013, FMCSA announced in a notice of final disposition titled, "Qualification of Drivers; Exemption Applications; Epilepsy and Seizure Disorders," (78 FR 3069), its decision to grant requests from 22 individuals for exemptions from the regulatory requirement that interstate CMV drivers have "no established medical history or clinical diagnosis of epilepsy or any other condition which is likely to cause loss of consciousness or any loss of ability to control a CMV." Since that time, the Agency has published additional notices granting requests from individuals for exemptions from the regulatory requirement regarding epilepsy found in § 391.41(b)(8).

To be considered for an exemption from the epilepsy and seizure disorders prohibition in § 391.41(b)(8), applicants must meet the criteria in the 2007 recommendations of the Agency's Medical Expert Panel (78 FR 3069).

## III. Qualifications of Applicants

### *Ashley Aucion*

Ashley Aucion is a 31-year-old class E license holder in Louisiana. They have a history of seizure disorder and have been seizure free since May 2014. They take anti-seizure medication with the dosage and frequency remaining the same since August 2013. Their physician states that they are supportive of Ashley Aucion receiving an exemption.

### *Colby Banks*

Colby Banks is a 31-year-old class C license holder in North Carolina. They have a history of seizure disorder and have been seizure free since 2004. They take anti-seizure medication with the dosage and frequency remaining the same since 2006. Their physician states that they are supportive of Colby Banks receiving an exemption.

### *Christopher Beaver*

Christopher Beaver is a 52-year-old class C license holder in Pennsylvania. They have a history of a single unprovoked seizure and have been seizure free since April 2014. They take anti-seizure medication with the dosage and frequency remaining the same since April 2014. Their physician states that they are supportive of Christopher Beaver receiving an exemption.

### *Emil Bigler*

Emil Bigler is a 71-year-old class A commercial driver's license (CDL) holder in Utah. They have a history of isolated seizure and have been seizure free since 1990. They take anti-seizure medication with the dosage and frequency remaining the same since 1990. Their physician states that they are supportive of Emil Bigler receiving an exemption.

### *Timothy Brinkman*

Timothy Brinkman is a 29-year-old class B CDL holder in Nebraska. They have a history of simple partial seizure disorder and have been seizure free since 2011. They take anti-seizure medication with the dosage and frequency remaining the same since March 2021. Their physician states that they are supportive of Timothy Brinkman receiving an exemption.

### *Alexander Carestia*

Alexander Carestia is a 30-year-old class C license holder in North Carolina. They have a history of generalized convulsion epilepsy and have been seizure free since 2014. They take anti-seizure medication with the dosage and frequency remaining the same since

2014. Their physician states that they are supportive of Alexander Carestia receiving an exemption.

*Kelly Craft*

Kelly Craft is a 52-year-old class D license holder in Minnesota. They have a history of focal epilepsy and have been seizure free since April 2015. They take anti-seizure medication with the dosage and frequency remaining the same since June 2021. Their physician states that they are supportive of Kelly Craft receiving an exemption.

*Nathan Gager*

Nathan Gager is a 40-year-old class D license holder in Minnesota. They have a history of juvenile myoclonic epilepsy and have been seizure free since 1997. They take anti-seizure medication with the dosage and frequency remaining the same since 2003. Their physician states that they are supportive of Nathan Gager receiving an exemption.

*Kenneth Gradoville*

Kenneth Gradoville is a 71-year-old class B CDL holder in Nebraska. They have a history of complex partial seizures and have been seizure free since 2007. They take anti-seizure medication with the dosage and frequency remaining the same since 2007. Their physician states that they are supportive of Kenneth Gradoville receiving an exemption.

*Winterhawk Hunter*

Winterhawk Hunter is a 43-year-old class AM CDL holder in Nevada. They have a history of epilepsy and have been seizure free since July 2000. They take anti-seizure medication with the dosage and frequency remaining the same since 2003. Their physician states that they are supportive of Winterhawk Hunter receiving an exemption.

*Donald Huntley*

Donald Huntley is a 23-year-old class D license holder in Ohio. They have a history of generalized epilepsy and have been seizure free since 2006. They take anti-seizure medication with the dosage and frequency remaining the same since 2019. Their physician states that they are supportive of Donald Huntley receiving an exemption.

*Samuel Isenberg*

Samuel Isenberg is a 64-year-old class C license holder in Pennsylvania. They have a history of gran mal seizure and have been seizure free since January 2004. They take anti-seizure medication with the dosage and frequency remaining the same since January 2014. Their physician states that they are

supportive of Samuel Isenberg receiving an exemption.

*Thomas Kepler*

Thomas Kepler is a 34-year-old class E license holder in Missouri. They have a history of epilepsy and have been seizure free since 2014. They take anti-seizure medication with the dosage and frequency remaining the same since 2016. Their physician states that they are supportive of Thomas Kepler receiving an exemption.

*Brian Manning*

Brian Manning is a 47-year-old class D license holder in New Jersey. They have a history of focal seizures and have been seizure free since 2012. They take anti-seizure medication with the dosage and frequency remaining the same since 2012. Their physician states that they are supportive of Brian Manning receiving an exemption.

*Devin McKain*

Devin McKain is a 28-year-old operator license holder in Indiana. They have a history of seizures and have been seizure free since May 2011. They take anti-seizure medication with the dosage and frequency remaining the same since August 2017. Their physician states that they are supportive of Devin McKain receiving an exemption.

*Jacob McNally*

Jacob McNally is a 29-year-old class A CDL holder in Connecticut. They have a history of seizure disorder and have been seizure free since 2015. They take anti-seizure medication with the dosage and frequency remaining the same since 2015. Their physician states that they are supportive of Jacob McNally receiving an exemption.

*Chris McNamara*

Chris McNamara is a 60-year-old class D license holder in New Hampshire. They have a history of seizure disorder and have been seizure free since 2012. They take anti-seizure medication with the dosage and frequency remaining the same since 2020. Their physician states that they are supportive of Chris McNamara receiving an exemption.

*Joseph Pitts*

Joseph Pitts is a 65-year-old class BM license holder in South Carolina. They have a history of seizure disorder and have been seizure free since 1973. They take anti-seizure medication with the dosage and frequency remaining the same since 1973. Their physician states that they are supportive of Joseph Pitts receiving an exemption.

*Joshua Ross*

Joshua Ross is a 39-year-old class D license holder in Delaware. They have a history of focal epilepsy and have been seizure free since 2002. They take anti-seizure medication with the dosage and frequency remaining the same since October 2020. Their physician states that they are supportive of Joshua Ross receiving an exemption.

*Shawn Springer*

Shawn Springer is a 38-year-old class D license holder in Minnesota. They have a history of epilepsy and have been seizure free since 2007. They take anti-seizure medication with the dosage and frequency remaining the same since 2005. Their physician states that they are supportive of Shawn Springer receiving an exemption.

*Ryan Webb*

Ryan Webb is a 43-year-old class C Chauffeur license holder in Michigan. They have a history of myoclonic epilepsy and have been seizure free since 1999. They take anti-seizure medication with the dosage and frequency remaining the same since January 2015. Their physician states that they are supportive of Ryan Webb receiving an exemption.

#### IV. Request for Comments

In accordance with 49 U.S.C. 31136(e) and 31315(b), FMCSA requests public comment from all interested persons on the exemption petitions described in this notice.

We will consider all comments received before the close of business on the closing date indicated under the **DATES** section of the notice.

**Larry W. Minor,**

*Associate Administrator for Policy.*

[FR Doc. 2023-16592 Filed 8-2-23; 8:45 am]

**BILLING CODE 4910-EX-P**

---

## DEPARTMENT OF TRANSPORTATION

### Maritime Administration

[Docket Number MARAD-2023-0163]

#### Request for Information: Center for Maritime Innovation

**AGENCY:** Maritime Administration (MARAD), Department of Transportation (DOT).

**ACTION:** Notice.

---

**SUMMARY:** This notice requests information from the public to assist MARAD in determining how best to organize and structure a Center for Maritime Innovation (the "Center").